Want to see TMDX full AI Analyst Report?

TransMedics Group (TMDX) Stock Forecast & Price Target

1,895 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TMDX Analyst Ratings

Moderate Buy

7 Buy

4 Hold

0 Sell

Based on 11 analysts giving stock ratings to

TransMedics

Group

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TMDX Stock 12 Month Forecast

Average Price Target

$97.44

▲(5.67% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for TransMedics Group in the last 3 months. The average price target is $97.44 with a high forecast of $122.00 and a low forecast of $65.00. The average price target represents a 5.67% change from the last price of $92.22.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"64":"$64","151":"$151","85.75":"$85.8","107.5":"$107.5","129.25":"$129.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":122,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$122.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":97.44444444444444,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$97.44</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$65.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[64,85.75,107.5,129.25,151],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,78.64,81.97538461538461,85.31076923076922,88.64615384615385,91.98153846153846,95.31692307692308,98.65230769230769,101.9876923076923,105.32307692307693,108.65846153846154,111.99384615384615,115.32923076923078,118.66461538461539,{"y":122,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,78.64,80.08649572649573,81.53299145299145,82.97948717948718,84.4259829059829,85.87247863247863,87.31897435897436,88.76547008547008,90.21196581196581,91.65846153846154,93.10495726495726,94.55145299145299,95.99794871794872,{"y":97.44444444444444,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,78.64,77.59076923076923,76.54153846153847,75.49230769230769,74.44307692307693,73.39384615384616,72.34461538461538,71.29538461538462,70.24615384615385,69.19692307692307,68.14769230769231,67.09846153846154,66.04923076923077,{"y":65,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":114.89,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":131.54,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":150.42,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.65,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":133.99,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":147,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.4,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.01,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.53,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.85,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.51,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.24,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.64,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$122.00

Average Price Target$97.44

Lowest Price Target$65.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Thomas Stephan

Stifel Nicolaus

$65

Hold

-29.52%

Downside

Reiterated

10/15/26

Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (NASDAQ: AQST) and TransMedics Group (NASDAQ: TMDX)

William Plovanic

Canaccord Genuity

$95→$94

Buy

1.93%

Upside

Reiterated

10/13/26

Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX), Bristol-Myers Squibb (NYSE: BMY) and Edgewise Therapeutics (NASDAQ: EWTX)

Christopher Pasquale

Barclays

$120

Buy

30.12%

Upside

Initiated

10/06/26

TransMedics initiated with an Overweight at BarclaysTransMedics initiated with an Overweight at Barclays

Matthew O'Brien

Piper Sandler

$100

Buy

8.44%

Upside

Reiterated

10/05/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Ryan Daniels

William Blair

―

Buy

―

Reiterated

10/02/26

Analyst Reiterates Buy on TransMedics, Citing Strong Near-Term Revenue Upside and Multiple Long-Term Growth Catalysts

Josh Jennings

TD Cowen

$120

Buy

30.12%

Upside

Reiterated

10/02/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: TransMedics Group (NASDAQ: TMDX), Regeneron (NASDAQ: REGN) and Tarsus Pharmaceuticals (NASDAQ: TARS)

Michael Matson

Needham

$106

Buy

14.94%

Upside

Assigned

09/22/26

Analysts Offer Insights on Healthcare Companies: DBV Technologies SA - American (NASDAQ: DBVT) and TransMedics Group (NASDAQ: TMDX)

Suraj Kalia

Oppenheimer

―

Hold

―

Reiterated

08/24/26

Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX) and NeoGenomics (NASDAQ: NEO)

Allen Gong

J.P. Morgan

$73

Hold

-20.84%

Downside

Reiterated

08/06/26

J.P. Morgan Sticks to Its Hold Rating for TransMedics Group (TMDX)

David Rescott

Robert W. Baird

$120→$122

Buy

32.29%

Upside

Reiterated

08/05/26

TransMedics price target raised to $122 from $120 at BairdTransMedics price target raised to $122 from $120 at Baird

Patrick Wood

UBS

$80→$77

Hold

-16.50%

Downside

Assigned

08/05/26

TransMedics price target lowered to $77 from $80 at UBSTransMedics price target lowered to $77 from $80 at UBS

Daniel Markowitz CFA

Evercore ISI

$100→$90

Buy

-2.41%

Downside

Reiterated

07/06/26

TransMedics price target lowered to $90 from $100 at Evercore ISITransMedics price target lowered to $90 from $100 at Evercore ISI

Young Li

Jefferies

$145

Buy

57.23%

Upside

Reiterated

10/28/25

Jefferies Sticks to Its Buy Rating for TransMedics Group (TMDX)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Thomas Stephan

Stifel Nicolaus

$65

Hold

-29.52%

Downside

Reiterated

10/15/26

Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (NASDAQ: AQST) and TransMedics Group (NASDAQ: TMDX)

William Plovanic

Canaccord Genuity

$95→$94

Buy

1.93%

Upside

Reiterated

10/13/26

Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX), Bristol-Myers Squibb (NYSE: BMY) and Edgewise Therapeutics (NASDAQ: EWTX)

Christopher Pasquale

Barclays

$120

Buy

30.12%

Upside

Initiated

10/06/26

TransMedics initiated with an Overweight at BarclaysTransMedics initiated with an Overweight at Barclays

Matthew O'Brien

Piper Sandler

$100

Buy

8.44%

Upside

Reiterated

10/05/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Ryan Daniels

William Blair

―

Buy

―

Reiterated

10/02/26

Analyst Reiterates Buy on TransMedics, Citing Strong Near-Term Revenue Upside and Multiple Long-Term Growth Catalysts

Josh Jennings

TD Cowen

$120

Buy

30.12%

Upside

Reiterated

10/02/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: TransMedics Group (NASDAQ: TMDX), Regeneron (NASDAQ: REGN) and Tarsus Pharmaceuticals (NASDAQ: TARS)

Michael Matson

Needham

$106

Buy

14.94%

Upside

Assigned

09/22/26

Analysts Offer Insights on Healthcare Companies: DBV Technologies SA - American (NASDAQ: DBVT) and TransMedics Group (NASDAQ: TMDX)

Suraj Kalia

Oppenheimer

―

Hold

―

Reiterated

08/24/26

Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX) and NeoGenomics (NASDAQ: NEO)

Allen Gong

J.P. Morgan

$73

Hold

-20.84%

Downside

Reiterated

08/06/26

J.P. Morgan Sticks to Its Hold Rating for TransMedics Group (TMDX)

David Rescott

Robert W. Baird

$120→$122

Buy

32.29%

Upside

Reiterated

08/05/26

TransMedics price target raised to $122 from $120 at BairdTransMedics price target raised to $122 from $120 at Baird

Patrick Wood

UBS

$80→$77

Hold

-16.50%

Downside

Assigned

08/05/26

TransMedics price target lowered to $77 from $80 at UBSTransMedics price target lowered to $77 from $80 at UBS

Daniel Markowitz CFA

Evercore ISI

$100→$90

Buy

-2.41%

Downside

Reiterated

07/06/26

TransMedics price target lowered to $90 from $100 at Evercore ISITransMedics price target lowered to $90 from $100 at Evercore ISI

Young Li

Jefferies

$145

Buy

57.23%

Upside

Reiterated

10/28/25

Jefferies Sticks to Its Buy Rating for TransMedics Group (TMDX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

IMUXImmunic

OMCLOmnicell

LGNDLigand Pharma

KURAKura Oncology

HITIHigh Tide

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering TransMedics Group

3 Months

William PlovanicCanaccord Genuity

Success Rate

22/42 ratings generated profit

Average Return

+8.69%

Copying William Plovanic's trades and holding each position for 3 Months would result in 52.38% of your transactions generating a profit, with an average return of +8.69% per trade.

1 Year

William PlovanicCanaccord Genuity

Success Rate

20/42 ratings generated profit

Average Return

+27.17%

Copying William Plovanic's trades and holding each position for 1 Year would result in 47.62% of your transactions generating a profit, with an average return of +27.17% per trade.

2 Years

William PlovanicCanaccord Genuity

Success Rate

18/42 ratings generated profit

Average Return

+45.74%

Copying William Plovanic's trades and holding each position for 2 Years would result in 42.86% of your transactions generating a profit, with an average return of +45.74% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TMDX Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TMDX has received 21 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. TMDX average Analyst price target in the past 3 months is 97.44.

Each month's total comprises the sum of three months' worth of ratings.

TMDX Financial Forecast

TMDX Earnings Forecast

Next quarter’s earnings estimate for TMDX is $0.30 with a range of $0.15 to $0.40. The previous quarter’s EPS was $0.44. TMDX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year TMDX has Performed in-line its overall industry.

TMDX Sales Forecast

Next quarter’s sales forecast for TMDX is $178.83M with a range of $170.00M to $188.45M. The previous quarter’s sales results were $189.95M. TMDX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year TMDX has Performed in-line its overall industry.

TMDX Stock Forecast FAQ

What is TMDX’s average 12-month price target, according to analysts?

Based on analyst ratings, TransMedics Group Inc’s 12-month average price target is 97.44.

What is TMDX’s upside potential, based on the analysts’ average price target?

TransMedics Group Inc has 5.67% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TMDX a Buy, Sell or Hold?

TransMedics Group Inc has a consensus rating of Moderate Buy which is based on 7 buy ratings, 4 hold ratings and 0 sell ratings.

What is TransMedics Group Inc’s price target?

The average price target for TransMedics Group Inc is 97.44. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $122.00 ,the lowest forecast is $65.00. The average price target represents 5.67% Increase from the current price of $92.22.

What do analysts say about TransMedics Group Inc?

TransMedics Group Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of TMDX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

TransMedics Group (TMDX) Stock Forecast & Price Target

TMDX Analyst Ratings

TMDX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering TransMedics Group

TMDX Analyst Recommendation Trends

TMDX Financial Forecast

TMDX Earnings Forecast

TMDX Sales Forecast

TMDX Stock Forecast FAQ

Detailed List of Analyst Forecasts